Member Info for pomander

I still take comfort from the whooping GBP equivalent �109,000,000 of shares traded in first two days post UK launch, in comparison just �189,000 in the lead up to 2017 results announcement. Still not a single II notifiable interest. I must say I am very confused.com as to management projections, SOTRR mentions US $250 m (whch I assume was put out at MI which would be perfectly acceptable) but is this retail sales or net sales? It is also lower than company projections in corporate presentations and indeed below EU projections (if retail). For the second year JG is a no sho, despite Ollie (I am assuming this) being informed by JM that he would be in attandance. What's that all about - surely a good opportunity for all to meet up.

Obtaining planning permission is not a critical success factor - surely it should be a given on a purpose built energy from waste site ? Of far greater challenge will be obtianing planning permissions for future Mosuetraps particularly if they are to be sited in the sort of locations advanced on here. Does KA enjoy good relationships with local councillors on a nationwide basis. Come on, its another load of old flannel, a diversion from the key objective of achieving a proven and tested commercial Mousetrap, which still seems far, far away. On funding, KA is hardly going to say he is looking at options to maximise the dilution that shareholders will suffer, although he is already doing a pretty good job on that front. Also a little worrying that the only feedstock that seems to fit the bill currently is shreeded, pre-screened tyre rubber. Seems to be a lot talking and little doing here.

On the FDA wall slide - the last company overview disclosed expected FDA approval in Q4 2019 - that appears to have been pushed back to 2020 - do we know why ?

Presumably Ollie your info originated from JM- little odd that he was under the impression that JG was attending, don't you think?

Thks SOTRR - much appreciated

Good thinking - it doesn't snow in HK !

Friday night beer time started early for some. Here's to strength and stability - hic !

I am being dumb Bignose - Master Investor

May I also wish you a very pleasant weekend and hope all goes well tomorrow.

Blimey - Friday afternoon Google Alerts are here !

A myocardial infarction is probably taking things too far ! Although you never know Viagra did the trick ! MI ?

If Red Wale GP courses are even mentioning Fortacin then surely that is a good thing. GPs, whilst unable to prescribe on NHS can nevertheless make sufferers aware of the only approved PE treatment, and point out that it will only be available by private Rx only - as when and if that happens. Otheriwse, comparisons with an off-lable, non approved, non prescibable treatments in a n on relevant territory and designed for minor surgeries a would seem to be a totally meaningless exercise. For those attending, hope tomorrow goes well.

Most likely a Placing - sounds more like a ''wish list'' than realistic expectations.

Complete red herring and not sure why the continued obsession with the UK market which is currently of little or no siginificance, other than the fact that you probaby live there. Fortacin has never been promoted by RP as being reimbursable. Th e 6 v 3 minute argumnet is complete clinically untested nonsense and I would suggest that anyone that wants sensationless sex, which maybe an attractive option for some, that they try Emla and other dodgy treatments currently being peddled. Impressive that your GP had even heard of Fortacin and balcklisted is not the correct term, the implications being clear- sounds to me like another mischief maker on board.

For anyone attending anything that you can glean on the following would be very useful 1) Current status on ROW licenses as from the language adopted these seem to have gone into reverse in regard to completion. 2) Current status on FDA submission 3) Clarification on projected net sales for Fortacin in E5. Dr Mike seemingly incorrectly referred to royalties based on gross retail sales (�232m) and last years presentation, rather than net sales (sales to wholesalers). 4) Any information/update on Fortacin viz-a-viz Viagra/Cialis failures. Sure others will also have questions, although with 2017 results due 23rd after the Board Meeting this might make it difficult.

I was stripping US T BIlls to swap the coupons for a major US bank 30 years ago, so thanks for the offer but I just about understand binary on a lucid day. If you wish to believe that 10 independent events with a 10% chance of success is the same as one with a 100% chance of success, then be my guest.

Thks Ollie.

Monkster - I think you are confusing probability theory with a series of uncorrelated binary outcomes. I made it clear that Summ may have 2 or 3 shots at goal but failure to score with one shot does not increase the probability to score with the second shot. Shots from the halfway line are also less favourable than those from the penalty spot.

Ollie - How did you establish JG was attending, we thought the same last year but he was a no show? Are you refering to the Board meeting to approve F/S next week ? I have checked the MasterInvestor website and I note RP or Dr Mike are not listed as speakers this year as he was last year on the rising stars stage. RP is only listed as an exhibitor this year. The MasterInvestor website also describes RP as being ��a diversified investment group currently holding various corporate and strategic investments across the healthcare and life sciences sectors�� Nonsense and untrue � why not just say that RP�s primary investment is Fortacin, the only approved treatment for PE which they believe has global blockbuster sales potential on a scale matched to Viagra.

All drugs are a binary play, you either achieve approval from the relevant authority or it fails, and in the case of the US you get a complete reposnse letter. Summ has more than one drug in its pipeline and these are statistically uncorrelated binary play's, or as have been described as more than one shot at goal. Whilst good news, this is far from being a game changer at this stage - as stated this arises from early testing and I suspect many pharma's would not even announce such news at this early stage. It also begs the question as to why Discuva sold out very recently as presumably they would have been aware of this likeley development? I remain concerned about the CEO's strategy and his ability to deliver, as demonstrated by events at Antisoma.